Trial details

Trial short name: SC.29

Official title: Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases

Principal Investigator: Dr. Alexander Louie

Cancer type: Central Nervous System
Cancer location: Other (Central Nervous System)
Disease stage: Advanced Cancer
Trial phase: Phase 3
Intervention: radiotherapy

Registration #: NCT06391242

Contact e-mail: cancerclinicaltrials@sunnybrook.ca

Trial description:
This study is being done to answer the following question: Is Stereotactic Body Radiation Therapy or SBRT (a form of radiation therapy which can deliver high doses of radiation to the specific painful area of the body most affected by cancer, while keeping the radiation beams away from the healthy parts of the body that surround the cancer) better for pain relief than the standard treatment of conventional radiation therapy or CRT (a form of radiation therapy which delivers radiation to the painful area but can also negatively affect other parts of the body in the same area)

Inclusion Criteria: • Histologic confirmation of solid tumour. • Patient with a dominant painful non-spine bone metastasis and a worst minimum pain score of 2 using the BPI attributed to that dominant site • Expected overall survival of greater than 6 months as determined by the treating physician • Suitable for protocol defined SBRT and CRT. • Stable pain with no immediate plan to alter analgesic regimen. • ECOG performance status of 0-2. • Participant consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each participant must sign a consent form prior to enrolment in the trial to document their willingness to participate Exclusion Criteria: • Metastases of the hands, feet, cranium and spine (including sacrum). • Bone metastasis arising from a small cell or germ cell. • Radionuclide therapy within 30 days of randomization. • Patient treated with prior palliative RT to the dominant painful bone metastasis site (prior radiation exposure is permitted if prior to development of the dominant metastasis and would not influence the applicability of either treatment arm of the current study). • Received systemic chemotherapy within 1 week of the protocol RT, or who are expected/planned to receive chemotherapy within one week of completing protocol RT. • Participants with an unstable pathologic fracture at the dominant painful bone metastasis, or for whom surgical fixation would be the preferred intervention if possible. • Pregnant or lactating individuals.